Physician profile
Mark E Pearson
NPI 1407857048
$30,204.96
in general payments reported to CMS, 2019-2025
9 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,960 · 2020: $18K · 2021: $3,907 · 2022: $163 · 2023: $482 · 2024: $61.23 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $400 · Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $400.00 |
| Food and Beverage | $261.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $29,176.48 | 2019-2021 | |
| Abbvie INC. | $418.80 | 2019-2025 | |
| Abbott Laboratories | $400.00 | 2023 | Cardiomems |
| Glaxosmithkline, LLC. | $58.04 | 2021-2025 | Benlysta |
| Amgen INC. | $54.41 | 2021-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2024-2025 | Saphnelo |
| Organon LLC | $22.53 | 2023 | Hadlima |
| Merck Sharp & Dohme LLC | $14.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.